Quince Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-75.5M | $35.9M | $-39.5M | $-13.4M | $-16.0M | $-15.0M | $-12.5M | $-5.5M |
| Depreciation & Amortization | $41.0K | $36.0K | $39.0K | $36.0K | $35.0K | $32.0K | $16.0K | $86.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $12.1M | $1.3M | $1.2M | $1.3M | $1.3M | $1.4M | $1.1M | $1.1M |
| Net Cash from Operating Activities | $-18.9M | $-7.6M | $-10.5M | $-9.9M | $-11.4M | $-9.6M | $-7.6M | $-7.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $0 | $4.0K | $74.0K | $126.0K | $148.0K | $133.0K | $46.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $8.0M | $12.0M | $8.1M | $-1.8M | $6.0M | $10.9M | $10.9M | $7.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $108.9M | $9.4M | $2.0M | $1.4M | $14.4M | $87.0K | $0 | $-5.0M |
| Net Change in Cash | $97.8M | $12.4M | $-643.0K | $-10.4M | $9.1M | $1.6M | $3.5M | $-5.2M |
| Free Cash Flow | $-18.9M | $-7.6M | $-10.5M | $-10.0M | $-11.5M | $-9.7M | $-7.7M | $-7.3M |